Articles From: Rich people prefer to bank with Wells Fargo, Bank of America to Eventure Interactive, Inc. Adds Ex-Google Executive, Jason Harvey, to its Senior Executive Team


2014/11/7
By Sital S.
Sign-up for Rich people prefer to bank with Wells Fargo, Bank of America investment picks
2014/11/7
By Sital S.
Sign-up for What to watch for in Berkshire Hathaway earnings investment picks
2014/11/13
By Sital S.
Sign-up for UPDATE: Duracell deal is a typical Warren Buffett play -- a bargain investment picks
2014/11/3
By Sital S.
Sign-up for What to watch for in Alibaba earnings investment picks
2014/10/30
By Sital S.
Sign-up for UPDATE: What to watch for in GoPro earnings investment picks
2014/10/29
By Sital S.
Sign-up for What to watch for in GoPro earnings investment picks
2014/11/10
By Sital S.
Sign-up for UPDATE: Rich people prefer to bank with Wells Fargo, Bank of America investment picks
2014/11/24
By Sital S.
Sign-up for UPDATE: How banks are looking more like tech companies investment picks
2014/12/10
By Sital S.
Sign-up for Retail sales expected to rise in November investment picks
2014/12/3
By Sital S.
Sign-up for More millennials use smartphones to watch their investments investment picks
2014/10/24
By Sital S.
Sign-up for UPDATE: Wells Fargo CEO defends bank's pay model investment picks
2014/10/23
By Sital S.
Sign-up for UPDATE: Wells Fargo CEO defends bank's pay model investment picks
2014/10/23
By Sital S.
Sign-up for Wells Fargo CEO defends bank's pay model investment picks
2014/11/25
By Sital S.
Sign-up for UPDATE: How banks are looking more like tech companies investment picks
2014/11/5
By Sital S.
Sign-up for Consolation prize for ousted politicians: Bigger salaries in the private sector investment picks
2014/11/3
By Sital S.
Sign-up for UPDATE: What to watch for in Alibaba earnings investment picks
2014/10/31
By Sital S.
Sign-up for UPDATE: What to watch for in AIG earnings investment picks
2014/10/30
By Sital S.
Sign-up for UPDATE: Analysts cheer Visa's better-than-expected quarter, shares rally 9% investment picks
2014/10/28
By Sital S.
Sign-up for What to watch for in Visa earnings investment picks
2014/11/13
By Sital S.
Sign-up for Duracell deal is a typical Warren Buffett play -- at a discount investment picks
2014/11/11
By Sital S.
Sign-up for UPDATE: Attorney general nominee Lynch expected to keep tabs on Wall Street investment picks
2014/12/2
By Sital S.
Sign-up for Large banks have paid $180 billion in fines since 2007 investment picks
2014/12/8
By Sital S.
Sign-up for Warren Buffett becomes world's 2nd-richest man investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don't meet a minimum 6-minute walk test score at baseline.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics today announced that it has initiated dosing in a confirmatory study of eteplirsen, the Company’s lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in ambulatory patients who meet specific criteria on their baseline 6-minute walk test score.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sarepta’s NDA submission.
Sign-up for Sarepta Therapeutics Announces Regulatory Update on Eteplirsen investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 168 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After more than three years of treatment, results of the 6-minute walk test (6MWT) at 168 weeks showed continued ambulation across all patients evaluable on the test, however all patients showed a decline in distance walked on this measure since the week 144 timepoint.
Sign-up for Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy investment picks
2015/1/20
The Coca-Cola Company today announced the 2014 winners of its “Shaping a Better Future Grant Challenge” – a competition exclusively for members of the World Economic Forum’s Global Shapers Community .
Sign-up for Coca-Cola and Global Shapers Community Announce Winners of the ‘Shaping a Better Future Grant Challenge’ investment picks
COSTA MESA, Calif., Nov.
Sign-up for Eventure Interactive, Inc. Finalizes Beta App for iOS Platform investment picks
COSTA MESA, Calif., Oct.
Sign-up for Eventure Interactive, Inc. Adds Ex-Google Executive, Jason Harvey, to its Senior Executive Team investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Rich people prefer to bank with Wells Fargo, Bank of America to Eventure Interactive, Inc. Adds Ex-Google Executive, Jason Harvey, to its Senior Executive Team
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent